Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mesoblast Ltd Ads (MESO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 570,670
  • Shares Outstanding, K 94,170
  • Annual Sales, $ 2,410 K
  • Annual Income, $ -76,810 K
  • 36-Month Beta 1.96
  • Price/Sales 228.79
  • Price/Cash Flow N/A
  • Price/Book 0.98

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.45 +7.52%
on 06/19/18
6.66 -12.01%
on 06/21/18
-0.23 (-3.78%)
since 05/22/18
3-Month
5.24 +11.83%
on 05/17/18
6.66 -12.01%
on 06/21/18
-0.20 (-3.30%)
since 03/22/18
52-Week
4.74 +23.63%
on 02/13/18
8.55 -31.46%
on 07/03/17
-2.02 (-25.63%)
since 06/22/17

Most Recent Stories

More News
Key Day 100 Survival Outcomes of Phase 3 Trial for Acute Graft Versus Host Disease Presented at 2018 ISSCR Annual Meeting

Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced key Day 100 survival outcomes of its Phase 3 trial for remestemcel-L, an allogeneic mesenchymal stem cell product candidate, in children with steroid...

MESO : 5.86 (-3.30%)
MSB : 24.75 (-0.30%)
U.S. Healthcare Leader Joseph R. Swedish Joins Mesoblast Board

Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that Joseph R. Swedish has joined its Board of Directors. Mr. Swedish has more than two decades of healthcare leadership experience as the CEO...

MESO : 5.86 (-3.30%)
ANTM : 244.82 (+0.72%)
MSB : 24.75 (-0.30%)
Investor Expectations to Drive Momentum within Mesoblast, Access National, Urogen Pharma, TechTarget, Sina, and CoStar Group -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mesoblast Limited (NASDAQ:MESO),...

MESO : 5.86 (-3.30%)
URGN : 52.42 (-4.38%)
CSGP : 412.09 (-0.72%)
TTGT : 29.14 (+1.08%)
ANCX : 30.19 (+0.40%)
SINA : 88.81 (+0.92%)
Financial Results and Operational Highlights for the Third Quarter Ended March 31, 2018

Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced strong financial results for the nine months ended March 31, 2018 and provided operational highlights for the third quarter ended March 31, 2018....

MESO : 5.86 (-3.30%)
MSB : 24.75 (-0.30%)
Mesoblast Appoints New Chief Financial Officer

Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced the appointment of Josh Muntner as its new Chief Financial Officer, based in New York.

MESO : 5.86 (-3.30%)
MSB : 24.75 (-0.30%)
Mesoblast Financial Results Webcast for Quarter Ended March 31, 2018

Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will report financial results for the quarter ended March 31, 2018 in a webcast beginning at 6:30 pm on Wednesday, May 30, 2018 EST; 8:30 am Thursday, May 31,...

MESO : 5.86 (-3.30%)
MSB : 24.75 (-0.30%)
Mesoblast Partners With Cartherics to Develop 'off-the-shelf' Cell-based Immunotherapies for Solid Cancers

Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has entered into a partnership with Cartherics Pty Ltd to develop allogeneic 'off-the-shelf' CAR-T cells armed with multiple targeting...

MESO : 5.86 (-3.30%)
MSB : 24.75 (-0.30%)
Mesoblast Phase 3 Trial Results for Acute Graft Versus Host Disease Presented at 2018 International Society for Cell and Gene Therapy Annual Meeting

Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that results of the Phase 3 trial evaluating its product candidate MSC-100-IV (remestemcel-L) in children with steroid-refractory acute Graft versus...

MESO : 5.86 (-3.30%)
MSB : 24.75 (-0.30%)
Mesoblast Cell Therapies Featured at Vatican International Healthcare Conference

Mesoblast's proprietary allogeneic cell technology platform was featured at the Unite to Cure Fourth International Vatican Conference on global healthcare initiatives held in Vatican City from April 26-28,...

MESO : 5.86 (-3.30%)
MSB : 24.75 (-0.30%)
Wired News - Mesoblast Announced Updated Data from Phase-3 and Phase-2b Clinical Trials of MPC-150-IM in Patients with Chronic Heart Failure

Stock Monitor: Caladrius Biosciences Post Earnings Reporting

MESO : 5.86 (-3.30%)
CLBS : 6.83 (-4.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade MESO with:

Business Summary

Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's...

See More

Key Turning Points

2nd Resistance Point 6.27
1st Resistance Point 6.06
Last Price 5.86
1st Support Level 5.70
2nd Support Level 5.55

See More

52-Week High 8.55
Fibonacci 61.8% 7.09
Fibonacci 50% 6.64
Fibonacci 38.2% 6.20
Last Price 5.86
52-Week Low 4.74

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar